Wissam El Atrouni, MD
Infectious Disease · Kansas City, KSNPI 1407829161
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,950 of the $14,781 with a category attached, or 80.8%. Viiv Healthcare Company accounts for 96.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $5,675 and has fallen 79.7% since, to $1,154 in 2025. Among infectious disease clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $547.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$14K
- Janssen Scientific Affairs, LLC$269
- Gilead$103
- Medtronic$79
- Merck$49
Across 2 payments — averaging $17,689 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$35K
What the payments were for
- Consulting fees$11,95081%
- Travel & lodging$1,59711%
- Food & beverage$1,2348%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 20 | $14,281 |
| Janssen Scientific Affairs, LLC | 3 | $269 |
| Gilead | 1 | $103 |
| Medtronic | 1 | $79 |
| Merck | 2 | $49 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,781 in reported general payments places this provider in the 95th percentile of 56 infectious disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 107 | $394,293 |
| RukobiaFostemsavir Tromethamine | 13 | $135,696 |
| DovatoDolutegravir Sodium/Lamivudine | 45 | $129,448 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 27 | $93,586 |
| PifeltroDoravirine | 33 | $69,672 |
| DescovyEmtricitabine/Tenofov Alafenam | 34 | $69,239 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $56,119 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $43,978 |
| Maraviroc | 21 | $37,725 |
| TivicayDolutegravir Sodium | 15 | $32,104 |
| IsentressRaltegravir Potassium | 15 | $25,377 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 25 | $3,709 |
| Amikacin Sulfate | 13 | $1,478 |
| Itraconazole | 11 | $1,315 |
| Ethambutol Hcl | 17 | $636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $103 | $507,509154 claims |
| Viiv Healthcare CompanyRukobia, Dovato, Triumeq, Tivicay | $14,281 | $390,835100 claims |
| MerckPifeltro, Isentress | $49 | $95,05048 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 56 infectious disease providers in Kansas.
Other infectious disease in Kansas City
- Dana HawkinsonKansas City$3K
- Glenn MackayKansas City$871
- Diana Benitez SanchezKansas City$412
- Phani AkellaKansas City$376
- Samuel WindhamKansas City$350
- Alex BeloteKansas City$287
- Skyler TrieuKansas City$240
- Austin PriceKansas City$238
- Benjamin HortonKansas City$211
- Lisa CloughKansas City$194
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.